Physician profile
John Lee
NPI 1184039240
$7,693.86
in general payments reported to CMS, 2019-2025
35 companies · $961 in 2025
The $961 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $290 · 2021: $734 · 2022: $950 · 2023: $1,003 · 2024: $3,138 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,554 · Travel and Lodging: $1,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,553.87 |
| Travel and Lodging | $1,548.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,107.28 | 2024-2025 | Ensite Precision, Ensite, Absolute Pro |
| Abbvie INC. | $1,525.26 | 2021-2025 | |
| Lilly USA, LLC | $772.56 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $586.37 | 2019-2025 | Wegovy, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $546.99 | 2019-2025 | Trintellix |
| Pfizer INC. | $382.72 | 2021-2025 | |
| Amgen INC. | $287.33 | 2019-2025 | Evenity, Prolia, Otezla |
| Exact Sciences Corporation | $171.76 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $163.22 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Allergan, INC. | $154.79 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.36 | 2019-2024 | Ofev |
| Glaxosmithkline, LLC. | $97.72 | 2019-2024 | Arexvy |
| Idorsia Pharmaceuticals US INC | $95.67 | 2022-2024 | Quviviq |
| Nevro Corp. | $81.74 | 2022-2023 | Senza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.58 | 2024-2025 | Caplyta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $69.29 | 2019-2023 | Spravato |
| Shire North American Group INC | $49.19 | 2019 | |
| Antares Pharma, INC. | $45.90 | 2019-2025 | Xyosted |
| Astellas Pharma US INC | $42.63 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.89 | 2022 | |
| Ironshore Pharmaceuticals INC. | $38.18 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.72 | 2019-2020 | |
| Axsome Therapeutics, INC. | $25.19 | 2023 | Auvelity |
| Merck Sharp & Dohme LLC | $24.31 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $22.44 | 2019 | |
| Corcept Therapeutics | $18.33 | 2023 | Korlym |
| Amarin Pharma, INC. | $16.91 | 2020 | |
| Lundbeck LLC | $16.45 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.36 | 2021 | |
| Sanofi Pasteur INC. | $14.03 | 2019 | |
| Daiichi Sankyo INC. | $12.68 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.38 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.24 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.58 | 2020 | |
| Grt US Holding, INC. | $9.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.